BEFORE THE ARIZONA MEDICAL BOARD

In the Matter of

CRYSTAL CUNNINGHAM, M.D.

Holder of License No. 58299 For the Practice of Allopathic Medicine In the State of Arizona. Case No. MD-23-0327A

AMENDED INTERIM CONSENT AGREEMENT FOR PRACTICE RESTRICTION

INTERIM CONSENT AGREEMENT

Crystal Cunningham, M.D. ("Respondent") elects to permanently waive any right to a hearing and appeal with respect to this Amended Interim Consent Agreement for Practice Restriction and consents to the entry of this Order by the Arizona Medical Board ("Board").

INTERIM FINDINGS OF FACT

- 1. The Board is the duly constituted authority for the regulation and control of the practice of allopathic medicine in the State of Arizona.
- 2. Respondent is the holder of License No. 58299 for the practice of allopathic medicine in the State of Arizona.
- 3. The Board initiated case number MD-23-0327A after receiving a complaint from a former employee of Respondent's practice alleging unprofessional practice by Respondent including treatment of patients while under the influence of controlled and illicit substances.
- 4. In her initial written response, Respondent stated that she acted as a Supervising Physician for PA NT, and provided a Delegation Agreement signed by PA NT on December 29, 2021. PA NT does not have an active Arizona Physician Assistant's license.

1

3

2

4 5

6

7

8

10

11

12

13

14 15

16

17

18 19

20

2122

23

24

- 5. Based on the information obtained during the course of the investigation, on June 6, 2023 the Executive Director issued an Interim Order for Physician Health Program Assessment ("Assessment Order") requiring Respondent to present for an Assessment with a Board approved Assessor within 10 days of the date of the Assessment Order.
- 6. Respondent informed Board staff that she would be on vacation out of state and requested a continuance of the deadlines in the Assessment Order to accommodate her plans.
- 7. On June 8, 2023 The Executive Director issued an Interim Order for Biological Fluid, Nail and/or Hair Testing requiring Respondent to complete drug testing no later than June 9, 2023 at 5:00 p.m. ("BFT Order"). Respondent failed to complete the testing within the deadline set in the BFT Order.
- 8. Board staff was able arrange for testing to be completed while Respondent was on vacation, and she did complete testing on June 13, 2023. Respondent tested positive for illicit substances.
- 9. On June 23, 2023, Respondent underwent an Assessment with a Board-approved Assessor. Based on the Assessment findings and results, the Assessor opined that Respondent was not safe to practice medicine.
- 10. Effective June 26, 2023, Respondent entered into an Interim Consent Agreement for Practice Restriction.
- 11. In his final report, the Assessor opined that Respondent could return to practice, provided she comply with recommendations for monitoring and aftercare and test negative for non-prescribed or illicit substances. The Assessor noted that Respondent reported being aware that PA NT was unlicensed, and that Respondent allowed an unlicensed staff member to initiate an IV. The Assessor recommended that these violations be addressed upon Respondent's return to practice.

- 12. Effective August 22, 2023 Respondent enrolled in private monitoring with a Board-approved Contractor, with requirements including random drug screening. The Contractor has notified the Board that Respondent is in compliance with monitoring requirements including serial drug screens negative for alcohol, non-prescribed controlled substances, or illicit substances.
- 13. The aforementioned information was presented to the investigative staff, the medical consultant and the lead Board member. All reviewed the information and concur that the interim consent agreement to restrict Respondent's practice is appropriate.
- 14. The investigation into this matter is pending and will be forwarded to the Board promptly upon completion for review and action.

INTERIM CONCLUSIONS OF LAW

- The Board possesses jurisdiction over the subject matter hereof and over Respondent.
- 2. Pursuant to A.R.S. § 32-1405(C)(25) the Executive Director has authority to enter into a consent agreement when there is evidence of danger to the public health and safety.
- 3. Pursuant to A.A.C. R4-16-504, the Executive Director may enter into an interim consent agreement when there is evidence that a restriction is needed to mitigate imminent danger to the public's health and safety. Investigative staff, the Board's medical consultant and the lead Board member have reviewed the case and concur that an interim consent agreement is appropriate.

INTERIM ORDER

IT IS HEREBY ORDERED THAT:

1. Upon compliance with paragraph 2, the Interim Consent Agreement is modified as follows: Respondent's practice is restricted in that Respondent shall practice

in a Board staff pre-approved group practice, and is prohibited from engaging in the solo practice of medicine. Prohibited solo practice includes, but is not limited to, a practice where 1) Respondent merely shares office space with another physician but is not affiliated for purposes of providing patient care, or 2) Respondent is the sole physician practitioner at that location. Respondent shall notify the Board within 10 days if she ceases practice in an approved group practice, and shall request Board staff pre-approval of any new group practice setting where she intends to practice medicine.

- 2. Within 5 days of the date of this agreement, Respondent shall provide the Board proof of enrollment with a PHP Contractor for participation in the Board's PHP for a period of five (5) years. Respondent shall comply with the following terms and conditions:
- 3. Respondent shall not consume alcohol or any food or other substance containing poppy seeds or alcohol.
- 4. Respondent shall not take any illegal drugs or mood altering medications unless prescribed for a legitimate therapeutic purpose.
- 5. Respondent shall attend the PHP's relapse prevention group therapy sessions one time per week for the duration of this Interim Consent Agreement, unless excused by the relapse prevention group facilitator for good cause. Individual relapse therapy may be substituted for one or more of the group therapy sessions, if PHP preapproves substitution. The relapse prevention group facilitators or individual relapse prevention therapist shall submit monthly reports to the PHP regarding attendance and progress.
- 6. Respondent shall continue to participate in any personalized aftercare programs or activities as recommended by the Assessor in his Assessment Report. Respondent shall report on those activities as requested by the PHP, including executing any releases necessary to allow the PHP to monitor her participation and communicate

directly with and obtain records from the treating providers for those aftercare activities.

Respondent shall be responsible for all costs of aftercare, including costs associated with compliance of this Interim Consent Agreement.

- 7. Respondent shall participate in a 12-step recovery program or other self-help program appropriate for substance abuse as recommended by the PHP. Respondent shall attend a minimum of three 12-step or other self-help program meetings per week. Two meetings per month must be Caduceus meetings. Respondent must maintain a log of all self-help meetings.
- 8. Respondent shall promptly obtain a Primary Care Physician ("PCP") and shall submit the name of the physician to the PHP in writing for approval. The approved PCP shall be in charge of providing and coordinating Respondent's medical care and treatment. Except in an *Emergency*, Respondent shall obtain medical care and treatment only from the PCP and from health care providers to whom the PCP refers Respondent. Respondent shall promptly provide a copy of this Interim Consent Agreement to the PCP. Respondent shall also inform all other health care providers who provide medical care or treatment that Respondent is participating in PHP. "Emergency" means a serious accident or sudden illness that, if not treated immediately, may result in a long-term medical problem or loss of life.
- 9. Respondent shall continue treatment with a PHP Contractor approved psychiatrist and psychotherapist as recommended by the Assessor in his Assessment Report and shall comply with any and all treatment recommendations, including taking any and all prescribed medications. Respondent shall instruct the treating professionals to submit quarterly written reports to the PHP regarding diagnosis, prognosis, current medications, recommendations for continuing care and treatment, and ability to safely practice medicine. The reports shall be submitted quarterly to the PHP, the

commencement of which to be determined by the PHP Contractor. Respondent shall provide the treating professionals with a copy of this Interim Consent Agreement. Respondent shall pay the expenses for treatment and be responsible for paying for the preparation of the quarterly reports.

- 10. All prescriptions for controlled substances shall be approved by the PHP prior to being filled except in an *Emergency*. Controlled substances prescribed and filled in an emergency shall be reported to the PHP within 48 hours. Respondent shall take no *Medication* unless the PCP or other health care provider to whom the PCP refers Respondent prescribes and the PHP approves the *Medication*. Respondent shall not self-prescribe any *Medication*. "Medication" means a prescription-only drug, controlled substance, and over-the counter preparation, other than plain aspirin, plain ibuprofen, and plain acetaminophen.
- 11. Respondent shall submit to random biological fluid, hair and/or nail testing for the remainder of this Interim Consent Agreement (as specifically directed below) to ensure compliance with PHP.
- 12. Respondent shall provide the PHP in writing with one telephone number that shall be used to contact Respondent on a 24 hour per day/seven day per week basis to submit to biological fluid, hair, and/or nail testing to ensure compliance with PHP. For the purposes of this section, telephonic notice shall be deemed given at the time a message to appear is left at the contact telephone number provided by Respondent. Respondent authorizes any person or organization conducting tests on the collected samples to provide testing results to the PHP. Respondent shall comply with all requirements for biological fluid, hair, and/or nail collection. Respondent shall pay for all costs for the testing.

-10

- 13. Respondent shall provide the PHP with written notice of any plans to travel out of state.
- 14. Respondent shall immediately notify the Board and the PHP in writing of any change in office or home addresses and telephone numbers.
- 15. Respondent provides full consent for the PHP to discuss the Respondent's case with the Respondent's PCP or any other health care providers to ensure compliance with PHP.
- 16. The relationship between the Respondent and the PHP is a direct relationship. Respondent shall not use an attorney or other intermediary to communicate with the PHP on participation and compliance issues. Any such questions should be directed to Board staff.
- 17. Respondent shall be responsible for all costs, including costs associated with participating in PHP, at the time service is rendered or within 30 days of each invoice sent to the Respondent. An initial deposit of two (2) months PHP fees is due upon entering the program. Failure to pay either the initial PHP deposit or monthly fees 60 days after invoicing will be reported to the Board by the PHP and may result in disciplinary action up to and including revocation.
- Agreement to all employers, hospitals and free standing surgery centers where Respondent currently has or in the future gains or applies for employment or privileges. Within 30 days of the date of this Interim Consent Agreement, Respondent shall provide the PHP with a signed statement of compliance with this notification requirement. Respondent is further required to notify, in writing, all employers, hospitals and free standing surgery centers where Respondent currently has or in the future gains or applies for employment or privileges of a violation of this Interim Consent Agreement.

- 19. In the event Respondent resides or practices as a physician in a state other than Arizona, Respondent shall participate in the rehabilitation program sponsored by that state's medical licensing authority or medical society. Respondent shall cause the monitoring state's program to provide written quarterly reports to the PHP regarding Respondent's attendance, participation, and monitoring. The monitoring state's program and Respondent shall immediately notify the PHP if Respondent is non-compliant with any aspect of the monitoring requirements or is required to undergo any additional treatment.
- 20. The PHP shall immediately notify the Board if Respondent is non-compliant with any aspect of this Interim Consent Agreement or is required to undergo any additional treatment.
- 21. Because this is an Interim Consent Agreement and not a final decision by the Board regarding the pending investigation, it is subject to further consideration by the Board. Once the investigation is complete, it will be promptly provided to the Board for its review and appropriate action.
- 22. Respondent may request, in writing, release and/or modification of this Interim Consent Agreement. Respondent's request must be accompanied by information demonstrating that Respondent is safe to practice medicine. The Executive Director, in consultation with and agreement of the lead Board member and the Chief Medical Consultant, has the discretion to determine whether it is appropriate to release Respondent from this Interim Consent Agreement.
- 23. The Board retains jurisdiction and may initiate new action based upon any violation of this Interim Consent Agreement, including, but not limited to, summarily suspending Respondent's license.

24. This Interim Consent Agreement shall be effective on the date signed by the Board's Executive Director.

DATED this ______, 2029.

ARIZONA MEDICAL BOARD

By Your & Me Soc

Patricia E. McSorley Executive Director

RECITALS

Respondent understands and agrees that:

- 1. The Board, through its Executive Director, may adopt this Interim Consent Agreement, or any part thereof, pursuant to A.R.S. § 32-1405(C)(25) and A.A.C. R4-16-504.
- 2. Respondent has read and understands this Interim Consent Agreement as set forth herein, and has had the opportunity to discuss this Interim Consent Agreement with an attorney or has waived the opportunity to discuss this Interim Consent Agreement with an attorney. Respondent voluntarily enters into this Interim Consent Agreement and by doing so agrees to abide by all of its terms and conditions.
- 3. By entering into this Interim Consent Agreement, Respondent freely and voluntarily relinquishes all rights to an administrative hearing on the matters set forth herein, as well as all rights of rehearing, review, reconsideration, appeal, judicial review or any other administrative and/or judicial action, concerning the matters related to the Interim Consent Agreement.
- 4. Respondent understands that this Interim Consent Agreement does not constitute a dismissal or resolution of this matter or any matters that may be currently

pending before the Board and does not constitute any waiver, express or implied, of the Board's statutory authority or jurisdiction regarding this or any other pending or future investigations, actions, or proceedings. Respondent also understands that acceptance of this Interim Consent Agreement does not preclude any other agency, subdivision, or officer of this State from instituting civil or criminal proceedings with respect to the conduct that is the subject of this Interim Consent Agreement. Respondent further does not relinquish Respondent's rights to an administrative hearing, rehearing, review, reconsideration, judicial review or any other administrative and/or judicial action, concerning the matters related to a final disposition of this matter, unless Respondent affirmatively does so as part of the final resolution of this matter.

- 5. Respondent acknowledges and agrees that upon signing this Interim Consent Agreement and returning it to the Board's Executive Director, Respondent may not revoke Respondent's acceptance of this Interim Consent Agreement or make any modifications to it. Any modification of this original document is ineffective and void unless mutually approved by the parties in writing.
- 6. Respondent understands that this Interim Consent Agreement shall not become effective unless and until it is signed by the Board's Executive Director.
- 7. Respondent understands and agrees that if the Board's Executive Director does not adopt this Interim Consent Agreement, Respondent will not assert in any future proceedings that the Board's consideration of this Interim Consent Agreement constitutes bias, prejudice, prejudgment, or other similar defense.

- 8. Respondent understands that this Interim Consent Agreement is a public record that may be publicly disseminated as a formal action of the Board, and that it shall be reported as required by law to the National Practitioner Data Bank.
- 9. Respondent understands that this Interim Consent Agreement does not alleviate Respondent's responsibility to comply with the applicable license-renewal statutes and rules. If this Interim Consent Agreement remains in effect at the time Respondent's allopathic medical license comes up for renewal, Respondent must renew the license if Respondent wishes to retain the license. If Respondent elects not to renew the license as prescribed by statute and rule, Respondent's license will not expire but rather, by operation of law (A.R.S. § 32-3202), become suspended until the Board takes final action in this matter. Once the Board takes final action, in order for Respondent to be licensed in the future, Respondent must submit a new application for licensure and meet all of the requirements set forth in the statutes and rules at that time.
- 10. Respondent understands that any violation of this Interim Consent Agreement constitutes unprofessional conduct under A.R.S. § 32-1401(27)(s) ("[v]iolating a formal order, probation, consent agreement or stipulation issued or entered into by the board or its executive director under this chapter.").

Crystal Curhingham (Dec 31, 2023 10:54 MST)
CRYSTAL M. CUNNINGHAM, M.D.

DATED: Dec 31, 2023

1	EXECUTED COPY of the foregoing e-mailed this <u>4th</u> day of <u>January</u> , 2024 to:
2	Colin Bell, Esq.
3	Stewart Law Group 202 East Earll Drive Suite 160
4	Phoenix, Arizona 85012 Attorney for Respondent
5	The transfer to open don't
6	ORIGINAL of the foregoing filed
7	this <u>4th</u> day of <u>January</u> , 2024 with:
8	Arizona Medical Board 1740 West Adams, Suite 4000
9	Phoenix, Arizona 85007
10	Einn Downey
11	Board staff
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	